TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Invex Therapeutics Ltd. ( (AU:IXC) ) has shared an update.
Invex Therapeutics Ltd has received notices from Celtic Capital Pte Ltd, which holds more than 5% of the company’s voting shares, requesting a general meeting to consider the removal of two directors. If the notices are valid, the company must hold the meeting within two months, potentially impacting its governance and strategic direction.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on repurposing the approved drug Exenatide for treating neurological conditions associated with raised intracranial pressure. The company has trademarked this repurposed drug as Presendin™.
Average Trading Volume: 51,105
Technical Sentiment Signal: Buy
Current Market Cap: A$7.52M
For a thorough assessment of IXC stock, go to TipRanks’ Stock Analysis page.